Latest Period
Q4 2025
Security Snapshot
Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) Institutional Ownership
CUSIP: 68235C206
13F Institutional Holders and Ownership History from Q2 2023 to Q1 2026
Institutions Reporting
34
Shares (Excl. Options)
16,651,600
Price
$7.50
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, no par value
- Symbol
- IMDX on Nasdaq
- Shares outstanding
- 32,330,312
- Price per share
- $3.21
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 16,651,600
- Total reported value
- $124,888,014
- % of total 13F portfolios
- 0%
- Share change
- +368,716
- Value change
- +$2,765,695
- Number of holders
- 34
- Price from insider filings
- $3.21
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value is tracked under CUSIP 68235C206.
- 34 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 34 to 13 between Q4 2025 and Q1 2026.
- Reported value moved from $124,888,014 to $3,180,524.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 34 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 68235C206?
CUSIP 68235C206 identifies IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68235C206:
Significant Owners of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 40% | +6.2% | $41,828,418 | +$2,454,098 | 12,835,134 | +6.2% | Neal C. Bradsher | 23 Apr 2026 |
| AWM Investment Company, Inc. | 10% | +31% | $9,685,464 | +$5,257,076 | 2,857,069 | +119% | AWM Investment Company, Inc. | 31 Mar 2025 |
As of 31 Dec 2025, 34 institutional investors reported holding 16,651,600 shares of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX). This represents 52% of the company’s total 32,330,312 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BROADWOOD CAPITAL INC | 35% | 11,410,100 | 0% | 5.2% | $85,575,750 |
| AWM Investment Company, Inc. | 8.7% | 2,814,230 | -0.29% | 2% | $21,106,725 |
| PURA VIDA INVESTMENTS, LLC | 2.9% | 947,134 | 0% | 27% | $7,103,505 |
| VANGUARD GROUP INC | 1.6% | 526,675 | +8.2% | 0% | $3,950,064 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.71% | 230,971 | +16% | 0% | $1,733,670 |
| BlackRock, Inc. | 0.41% | 131,361 | +49% | 0% | $985,208 |
| 683 Capital Management, LLC | 0.24% | 77,204 | 0.05% | $579,030 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.22% | 72,451 | 0% | $543,383 | |
| MILLENNIUM MANAGEMENT LLC | 0.19% | 61,377 | -16% | 0% | $460,328 |
| NORTHERN TRUST CORP | 0.15% | 48,858 | +49% | 0% | $366,435 |
| STATE STREET CORP | 0.15% | 47,754 | +14% | 0% | $358,155 |
| JANE STREET GROUP, LLC | 0.13% | 42,469 | 0% | $318,517 | |
| FNY Investment Advisers, LLC | 0.13% | 40,584 | -24% | 0.09% | $304,000 |
| MORGAN STANLEY | 0.11% | 35,913 | -42% | 0% | $269,348 |
| Qube Research & Technologies Ltd | 0.09% | 28,351 | 0% | $212,633 | |
| OMERS ADMINISTRATION Corp | 0.08% | 26,164 | 0% | $196,230 | |
| OSAIC HOLDINGS, INC. | 0.07% | 24,136 | +115% | 0% | $181,019 |
| GOLDMAN SACHS GROUP INC | 0.07% | 23,965 | 0% | $179,738 | |
| CITADEL ADVISORS LLC | 0.05% | 15,647 | +33% | 0% | $117,353 |
| RENAISSANCE TECHNOLOGIES LLC | 0.04% | 13,400 | -43% | 0% | $100,500 |
| Hudson Bay Capital Management LP | 0.04% | 13,061 | 0% | $97,958 | |
| Private Advisor Group, LLC | 0.03% | 10,416 | 0% | 0% | $78,120 |
| EverSource Wealth Advisors, LLC | 0.02% | 5,000 | 0% | 0% | $37,500 |
| UBS Group AG | 0.01% | 2,941 | +8.4% | 0% | $22,058 |
| ORG Partners LLC | 0% | 450 | 0% | 0% | $3,375 |
Institutional Holders of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 969,837 | $3,180,524 | +$744,462 | $3.28 | 13 |
| 2025 Q4 | 16,651,600 | $124,888,014 | +$2,765,695 | $7.50 | 34 |
| 2025 Q3 | 16,282,884 | $54,051,121 | +$296,694 | $3.32 | 27 |
| 2025 Q2 | 15,248,594 | $46,050,393 | +$442,513 | $3.02 | 29 |
| 2025 Q1 | 16,047,858 | $49,105,818 | +$23,516,169 | $3.06 | 29 |
| 2024 Q4 | 8,368,639 | $19,916,902 | +$2,876,004 | $2.38 | 25 |
| 2024 Q3 | 7,107,091 | $20,255,014 | +$3,161,741 | $2.85 | 19 |
| 2024 Q2 | 5,990,280 | $17,670,609 | +$7,170,223 | $2.95 | 21 |
| 2024 Q1 | 3,559,240 | $10,429,392 | -$189,496 | $2.93 | 22 |
| 2023 Q4 | 3,624,342 | $9,059,295 | -$247,783 | $2.50 | 24 |
| 2023 Q3 | 3,718,862 | $11,617,455 | +$11,614,005 | $3.12 | 26 |
| 2023 Q2 | 15,000 | $3,450 | +$3,450 | $0.23 | 1 |